Pretreatment karyotype and best response to imatinib in patients with clonal evolution and other accelerated phase features (HEM-AP + CE; n = 24)
| Case no. . | Pretreatment karyotype . | Best response . |
|---|---|---|
| 1 | 46, XY, t(9;22)[12]/46, XY, der(9)t(9;22),idicder(22q)[7]/ 47, XY, t(9;22),+ der(22)t(9;22)[1] | (FISH 51.5%, Ph 89%) |
| 2 | 46, XY, t(9;22) [16]/49,XY, t(9;22),+ 19,+ 21,+ der(22) t(9;22)[4] | (FISH 85.5%, Ph 100%, progression) |
| 3 | 46, XX, t(9;22) [16]/45,XX, t(9;22),t(15;18)(p11;q11),− 18[5] | (FISH 45.5%, Ph 100%) |
| 4 | 46, XY, t(9;22),t(12;14)(?q24;?q23)[22] | (FISH 12.5%, Ph 5%) |
| 5 | 46, XX, t(9;22),del(18)(q21.3)[1]/47,idem,+ 8[18]/47,idem,− 1,del(2)(q21),− 6,− 7,+ 8, t(9;22) (q34;q11.2),add(11)(q34),− 13,del(18)(q21.3),add(19)(q13),+ mar1,mar2,+ mar3,+ mar4[1] | (FISH 3.5%, Ph 0%) |
| 6 | 46, XY, t(3;21)(q26.2;q22),t(9;22) [23] | (FISH 36.5%, no metaphases for analysis) |
| 7 | 46, XX, t(9;22;12),t(3;der(12))(p22;q14),t(9;10)(q3?2;q2?2), del(13)(q14),del(11)(q13), t(11;17)(q23;p13)[20] | (progression) |
| 8 | 46, XY, t(9;22),− 17[1]/46-47,idem,+ r1,+ r2[cp18] | (FISH 61.5%, Ph 90%, progression) |
| 9 | 46, XY, t(3;7)(p21;p15),t(9;22),t(10;11)(p15;q23)[17]/46,XY,t(9;22) [5] | (FISH 25%, Ph 19%, progression) |
| 10 | 45, XY,der(7)t(7;17)(p13;q11),t(9;22),− 17[11]/46, XY, t(9;22) [9] | (FISH 90%, Ph 100%, progression) |
| 11 | 45, XX, add(6)(p25),der(9),t(9;22),− 22[18]/45,XX,der(9)t(9;22),− 14,add(16)(q22),add(17)(p12),+ 21,− 22[2] | (FISH 74%, Ph 100%, progression) |
| 12 | 46, XY, t(9;22) [18]/46,idem,iso(17)(q11.2)[2] | (FISH 83%, Ph 100%) |
| 13 | 46, XY, t(9;22),add(19)(q13)[20] | (FISH 43%, Ph 100%) |
| 14 | 46, XX, t(9;22)[16]/46,idem,t(10;12;11;16)(q23;q13;q11;q12)[5] | (FISH 60.5%, Ph 100%, progression) |
| 15 | 46, XX, t(3;19)(p21;p13),t(9;22) [20] | (FISH 63%, Ph 100%, progression) |
| 16 | 46, XY del(3)(q21), t(9;22) (q34;q11),add(17)(q25),add(21)(q22)[20] | (FISH 79%, Ph 95%, progression) |
| 17 | 46, XY, t(9;22;15) (q34;q11.2;q15),add(19)(p13.3)[5]/46,XY,t(9;22;15)[15] | (FISH 77%, Ph 100%) |
| 18 | 46, XY, t(9;22) [1]/45,XY, t(9;22) (q34;q11),der(14;17)(q10;q10)[19] | (progression) |
| 19 | 46, XY, t(9;22),− 17,add(19)(q13.4),+ mar[19]/46,XY, t(9;22),− 17,add(19)(q13.4)[1] | (FISH 83.5%, Ph 100%, progression) |
| 20 | 46, XX, t(9;22)[14]/45,XX,der(9)t(9;22),− 22[6] | (FISH 64%, Ph 100%, progression) |
| 21 | 46, XY, t(9;22)[17]/ 47,idem,+ der(22)t(9;22)[3] | (progression) |
| 22 | 46, XY, t(3;14)(p21;q32),t(9;22)[20] | (FISH 1.5%, Ph 0%) |
| 23 | 46, XY, t(9;22)[14]/45,X,− Y, t(9;22)[6] | (FISH 4%, Ph -no metaphases) |
| 24 | 46, XY,t(9;22)[8]/46,idem,add(1)(p36.3)[12] | (FISH 34.5%, Ph 100%, progression) |
| Case no. . | Pretreatment karyotype . | Best response . |
|---|---|---|
| 1 | 46, XY, t(9;22)[12]/46, XY, der(9)t(9;22),idicder(22q)[7]/ 47, XY, t(9;22),+ der(22)t(9;22)[1] | (FISH 51.5%, Ph 89%) |
| 2 | 46, XY, t(9;22) [16]/49,XY, t(9;22),+ 19,+ 21,+ der(22) t(9;22)[4] | (FISH 85.5%, Ph 100%, progression) |
| 3 | 46, XX, t(9;22) [16]/45,XX, t(9;22),t(15;18)(p11;q11),− 18[5] | (FISH 45.5%, Ph 100%) |
| 4 | 46, XY, t(9;22),t(12;14)(?q24;?q23)[22] | (FISH 12.5%, Ph 5%) |
| 5 | 46, XX, t(9;22),del(18)(q21.3)[1]/47,idem,+ 8[18]/47,idem,− 1,del(2)(q21),− 6,− 7,+ 8, t(9;22) (q34;q11.2),add(11)(q34),− 13,del(18)(q21.3),add(19)(q13),+ mar1,mar2,+ mar3,+ mar4[1] | (FISH 3.5%, Ph 0%) |
| 6 | 46, XY, t(3;21)(q26.2;q22),t(9;22) [23] | (FISH 36.5%, no metaphases for analysis) |
| 7 | 46, XX, t(9;22;12),t(3;der(12))(p22;q14),t(9;10)(q3?2;q2?2), del(13)(q14),del(11)(q13), t(11;17)(q23;p13)[20] | (progression) |
| 8 | 46, XY, t(9;22),− 17[1]/46-47,idem,+ r1,+ r2[cp18] | (FISH 61.5%, Ph 90%, progression) |
| 9 | 46, XY, t(3;7)(p21;p15),t(9;22),t(10;11)(p15;q23)[17]/46,XY,t(9;22) [5] | (FISH 25%, Ph 19%, progression) |
| 10 | 45, XY,der(7)t(7;17)(p13;q11),t(9;22),− 17[11]/46, XY, t(9;22) [9] | (FISH 90%, Ph 100%, progression) |
| 11 | 45, XX, add(6)(p25),der(9),t(9;22),− 22[18]/45,XX,der(9)t(9;22),− 14,add(16)(q22),add(17)(p12),+ 21,− 22[2] | (FISH 74%, Ph 100%, progression) |
| 12 | 46, XY, t(9;22) [18]/46,idem,iso(17)(q11.2)[2] | (FISH 83%, Ph 100%) |
| 13 | 46, XY, t(9;22),add(19)(q13)[20] | (FISH 43%, Ph 100%) |
| 14 | 46, XX, t(9;22)[16]/46,idem,t(10;12;11;16)(q23;q13;q11;q12)[5] | (FISH 60.5%, Ph 100%, progression) |
| 15 | 46, XX, t(3;19)(p21;p13),t(9;22) [20] | (FISH 63%, Ph 100%, progression) |
| 16 | 46, XY del(3)(q21), t(9;22) (q34;q11),add(17)(q25),add(21)(q22)[20] | (FISH 79%, Ph 95%, progression) |
| 17 | 46, XY, t(9;22;15) (q34;q11.2;q15),add(19)(p13.3)[5]/46,XY,t(9;22;15)[15] | (FISH 77%, Ph 100%) |
| 18 | 46, XY, t(9;22) [1]/45,XY, t(9;22) (q34;q11),der(14;17)(q10;q10)[19] | (progression) |
| 19 | 46, XY, t(9;22),− 17,add(19)(q13.4),+ mar[19]/46,XY, t(9;22),− 17,add(19)(q13.4)[1] | (FISH 83.5%, Ph 100%, progression) |
| 20 | 46, XX, t(9;22)[14]/45,XX,der(9)t(9;22),− 22[6] | (FISH 64%, Ph 100%, progression) |
| 21 | 46, XY, t(9;22)[17]/ 47,idem,+ der(22)t(9;22)[3] | (progression) |
| 22 | 46, XY, t(3;14)(p21;q32),t(9;22)[20] | (FISH 1.5%, Ph 0%) |
| 23 | 46, XY, t(9;22)[14]/45,X,− Y, t(9;22)[6] | (FISH 4%, Ph -no metaphases) |
| 24 | 46, XY,t(9;22)[8]/46,idem,add(1)(p36.3)[12] | (FISH 34.5%, Ph 100%, progression) |
Progression indicates transformation to blast crisis.